Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Translation01:31

Translation

141.9K
Lesson: Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of...
141.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Erythropoiesis01:14

Erythropoiesis

4.2K
Red blood cells  (RBCs) transport oxygen to all body tissues. These cells survive only for 120 days and then need to be replenished. Erythropoiesis is the process of RBC production. In healthy individuals, erythropoiesis ensures all tissues are amply supplied with oxygen. In addition, blood loss due to injury leads to a drop in the physiological oxygen level that will cause erythropoiesis. Any defect in erythropoiesis leads to several physiological disorders, including thalassemia, anemia,...
4.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

329
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
329
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

13.2K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
13.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The ASPHO 2025 Distinguished Career Award to Dr Peter E. Newburger.

Pediatric blood & cancer·2026
Same author

Inherited thrombocytopenia and Occam's razor.

Blood·2017
See all related articles

Related Experiment Video

Updated: Jun 30, 2025

Author Spotlight: Advancing Erythropoiesis Research - A Simplified Pipeline for Assessing Hematopoietic Stem Cell Function in Myelodysplastic Syndromes
08:53

Author Spotlight: Advancing Erythropoiesis Research - A Simplified Pipeline for Assessing Hematopoietic Stem Cell Function in Myelodysplastic Syndromes

Published on: January 10, 2025

477

Understanding complex disease-related mechanisms: Rational therapies for Diamond-Blackfan anaemia.

Jeffrey M Lipton1

  • 1Division of Hematology Oncology Stem Cell Transplant/Cellular Therapy, Cohen Children's Medical Center, Northwell Health, New Hyde Park, New York, USA.

British Journal of Haematology
|March 14, 2024
PubMed
Summary

Eltrombopag, a thrombopoietin-mimetic agent, was investigated for treating Diamond-Blackfan anaemia (DBA), a rare red cell failure disorder. While the response rate was low, this study offers valuable insights into potential therapies for refractory DBA.

Keywords:
Diamond–Blackfan anaemiaas congenital hypoplastic anemiaeltrombopag

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.3K
A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
07:24

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy

1.7K

Related Experiment Videos

Last Updated: Jun 30, 2025

Author Spotlight: Advancing Erythropoiesis Research - A Simplified Pipeline for Assessing Hematopoietic Stem Cell Function in Myelodysplastic Syndromes
08:53

Author Spotlight: Advancing Erythropoiesis Research - A Simplified Pipeline for Assessing Hematopoietic Stem Cell Function in Myelodysplastic Syndromes

Published on: January 10, 2025

477
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.3K
A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
07:24

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy

1.7K

Area of Science:

  • Paediatric Haematology
  • Rare Blood Disorders
  • Clinical Trials

Background:

  • Diamond-Blackfan anaemia (DBA), also known as congenital hypoplastic anaemia, is a rare inherited bone marrow failure syndrome.
  • DBA is characterized by erythroid aplasia, leading to severe anaemia and potential complications.
  • Current treatment options for refractory or relapsed DBA are limited, highlighting the need for novel therapeutic strategies.

Purpose of the Study:

  • To evaluate the efficacy and safety of eltrombopag, a thrombopoietin-mimetic agent, in patients with refractory or relapsed Diamond-Blackfan anaemia.
  • To assess the impact of eltrombopag on red blood cell production and transfusion requirements in DBA patients.

Main Methods:

  • A clinical trial was conducted to treat patients with refractory/relapsed DBA using eltrombopag.
  • The study involved administering eltrombopag and monitoring treatment response, including haematological parameters and transfusion needs.

Main Results:

  • The clinical trial demonstrated a low response rate to eltrombopag in patients with refractory/relapsed Diamond-Blackfan anaemia.
  • Despite the low overall response, the study provides crucial data on the use of eltrombopag in this challenging patient population.
  • Further investigation is warranted to understand the mechanisms of response and non-response to eltrombopag in DBA.

Conclusions:

  • Eltrombopag showed limited efficacy as a treatment for refractory/relapsed Diamond-Blackfan anaemia in this trial.
  • The study underscores the complexity of DBA pathophysiology and the challenges in developing effective therapies.
  • This research contributes valuable clinical data, informing future therapeutic approaches for Diamond-Blackfan anaemia.